New drug aims to stop weight loss in lung cancer patients during treatment

NCT ID NCT07150663

Recruiting now Symptom relief Sponsor: Changchun GeneScience Pharmaceutical Co., Ltd. Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 26, 2026 · Updated 1 time

Summary

This phase 3 trial tests whether a drug called nanocrystalline megestrol acetate can help people with advanced non-small cell lung cancer maintain their appetite and avoid significant weight loss while undergoing chemoradiotherapy. About 134 participants will receive either the drug or a placebo alongside standard treatment for up to 8 weeks. The goal is to improve quality of life during a tough treatment period.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: nanocrystalline megestrol acetate
What this could lead to: If it works, this could offer a way to help people with advanced lung cancer maintain their appetite and weight during intensive chemoradiotherapy.
What could go wrong: This is a phase 3 trial, but it focuses on symptom relief, not curing the cancer. The benefits may be modest, and side effects from the drug are possible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for NON-SMALL CELL LUNG CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

non-small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

NON-SMALL CELL LUNG CANCER

Contacts and locations

Locations

Tongji Hospital, TongjiMedical College, Huazhong University of Science and Technology
RECRUITING

Wuhan, Hubei, 430000, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.